Technicals — Down 6.3% to $205.84, a single-day break of the consolidation shelf above the 20-day on heavier volume. Price technically holds the 50-day ($201.4), but one long red candle wrecked the momentum structure, with RSI dumping from 60+ to 53.8.
Fundamentals — Morgan Stanley's downgrade lands a triple hit: capped near-term margin growth, Philips potentially re-entering the US PAP market, and GLP-1 drugs structurally eroding sleep-apnea treatment demand. The first two are cyclical; the third is structural — and the root of a year of multiple compression. A $1.25M CEO share sale adds to the shadow.
News — Fell 6.3% on 7/8 on the Morgan Stanley downgrade, leading med-tech lower. The stock is down 23% over 12 months — the GLP-1 erosion thesis returns every few months to harvest momentum buyers.
Stopped out (~-5.7%): the entry thesis was momentum continuation above the moving averages, and a 6.3% downgrade candle shattered it in one session. GLP-1 is a structural overhang — not something worth testing with open risk.
Sleep-apnea penetration remains low and the device-plus-consumables model throws off quality cash flow, but GLP-1's erosion of the demand curve can't be falsified; a re-rating needs successive quarters proving demand resilience.
- Expanding GLP-1 indications directly shrink the patient pool
- A Philips US comeback triggers price competition
- FX and reimbursement policy noise
- StockTwits · Yesterday the board counted gains off the 52-week low; today everyone asks how much demand GLP-1 really eats. The question never changed — who's asking didOriginal ↗
- 华尔街共识 · 30 analysts average $270 (+31% vs. spot), but the Morgan Stanley cut cracks the consensus
- Morgan Stanley · Cut to Equalweight: margin pressure, Philips re-entry risk, long-run GLP-1 demand erosionSource ↗
